| Patents for A61K 38 - Medicinal preparations containing peptides (316,240) |
|---|
| 01/03/2002 | US20020001807 Nucleotide sequences coding enzymatic polypeptide; for use in the diagnosis and treatment of cancer |
| 01/03/2002 | US20020001806 Nucleotide sequences coding enzymatic polypeptde for use in the prevention of apoptosis; neuroprotective agents; antitumor agents |
| 01/03/2002 | US20020001798 Neutralizing high affinity human monoclonal antibodies specific to RSV F-protein and methods for their manufacture and therapeutic use thereof |
| 01/03/2002 | US20020001631 Human growth hormone |
| 01/03/2002 | US20020001629 Pretreatment; inducing stress response |
| 01/03/2002 | US20020001625 Pharmaceutical or veterinary composition for treating wounds comprising milk product extracts including growth factors with basic to neutral isoelectric points |
| 01/03/2002 | US20020001624 Medicinal product for the promotion of wound healing |
| 01/03/2002 | US20020001615 Combined interferon alfa and lipsosmal-encapsulated all-trans retinoic acid, including preparation and use |
| 01/03/2002 | US20020001610 Active ingredient delivery systems and devices based on porous matrices |
| 01/03/2002 | US20020001600 Method of using lectins for prevention and treatment of skin diseases and disorders |
| 01/03/2002 | US20020001592 Use of Botulinum toxins for treating various disorders and conditions and associated pain |
| 01/03/2002 | US20020001591 Compositions for the delivery of antigens |
| 01/03/2002 | US20020001585 Administering a blocking agent of tumor necrosis factors or receptors; treatment of Sin Nombre (SNV), Ebola, Marburg, Lassa, and Dengue viral disease |
| 01/03/2002 | US20020001583 Zace1: a human metalloenzyme |
| 01/03/2002 | US20020001576 Medicaments containing allogenic activated-CD4+ cells as the main ingradient, which are attributable to an organ or bone marrow implant donor, have extreemly beneficial effect for preventing tumor and various infections |
| 01/03/2002 | US20020001575 Nutritional system for nervous system disorders |
| 01/03/2002 | US20020001332 Mounting arrangement for auxiliary burner or lance |
| 01/03/2002 | DE10031044A1 Endoparasitizide Mittel zur freiwilligen oralen Aufnahme durch Tiere Endoparasiticides means of voluntary oral ingestion by animals |
| 01/03/2002 | DE10029404A1 Colloidal cyclosporin formulation for treatment and prevention of skin and mucous membrane disorders contains cyclosporin, lipophilic phase, mixture of surfactant and cosurfactant and hydrophilic phase |
| 01/03/2002 | DE10029131A1 New nucleic acid encoding protein kinase of the mitogenic signaling pathway, useful for identifying cytostatic agents, includes the sequence of a glycolytic enzyme binding site |
| 01/03/2002 | DE10028204A1 Verfahren zur Auffindung von medizinisch wertvollen Wirkstoffen Method for identifying medically valuable active ingredients |
| 01/03/2002 | CA2709771A1 Compositions and methods for the diagnosis and treatment of disorders involving angiogenesis |
| 01/03/2002 | CA2648051A1 Compositions and methods for the diagnosis and treatment of disorders involving angiogenesis |
| 01/03/2002 | CA2648048A1 Compositions and methods for the diagnosis and treatment of disorders involving angiogenesis |
| 01/03/2002 | CA2648046A1 Compositions and methods for the diagnosis and treatment of disorders involving angiogenesis |
| 01/03/2002 | CA2417699A1 Helicobacter pylori heptosyl transferase polypeptides |
| 01/03/2002 | CA2415238A1 Peptides for the preparation of vaccines against bordetella pertussis and bordetella parapertussis |
| 01/03/2002 | CA2415236A1 Novispirins: antimicrobial peptides |
| 01/03/2002 | CA2414401A1 Targeted delivery of cytotoxic drugs a) to activated lymphocytes in patients with transplanted organs, b) as radiosensitizers to cancer cells in patients undergoing radiation therapy, and c) in vitamin-binding proteins as drug carriers in the diagnosis and treatment of cancer |
| 01/03/2002 | CA2414342A1 Materials and methods relating to the increase in protein activity |
| 01/03/2002 | CA2414308A1 Transport peptides derived from erns protein, cytotoxic rnase of ribosome-inactivating protein or a rsv g-protein and analogues thereof |
| 01/03/2002 | CA2414303A1 Materials and methods relating for the treatment and diagnosis of pre-eclampsia |
| 01/03/2002 | CA2414210A1 Novel therapeutic molecular variants and uses thereof |
| 01/03/2002 | CA2413768A1 Pharmaceutical compositions for angiogenic therapy |
| 01/03/2002 | CA2413742A1 Prion-binding activity in serum and proteins |
| 01/03/2002 | CA2413673A1 Thymic stromal lymphopoietin receptor molecules and uses thereof |
| 01/03/2002 | CA2413547A1 B7-like molecules and uses thereof |
| 01/03/2002 | CA2413543A1 Human papilloma virus treatment |
| 01/03/2002 | CA2413354A1 Neurotoxic a.beta. oligomers in alzheimer's disease |
| 01/03/2002 | CA2413338A1 Protein mixtures for wound healing |
| 01/03/2002 | CA2413301A1 Methods for using tetanus toxin for benificial purposes in animals (mammals) |
| 01/03/2002 | CA2413209A1 Modulation of a.beta. levels by .beta.-secretase bace2 |
| 01/03/2002 | CA2413201A1 Treatment for cardiovascular disease |
| 01/03/2002 | CA2413157A1 Biodegradable vehicles and delivery systems of biologically active substances |
| 01/03/2002 | CA2412701A1 Methods for producing modified glycoproteins |
| 01/03/2002 | CA2412637A1 Replication deficient adenoviral tnf vector |
| 01/03/2002 | CA2412635A1 Novel proteases |
| 01/03/2002 | CA2412612A1 Eg-vegf nucleic acids and polypeptides and methods of use |
| 01/03/2002 | CA2412610A1 Gp286 nucleic acids and polypeptides |
| 01/03/2002 | CA2412256A1 Polynucleotides and polypeptides encoded thereby |
| 01/03/2002 | CA2412211A1 Compositions and methods for the diagnosis and treatment of disorders involving angiogenesis |
| 01/03/2002 | CA2411828A1 Novel co-stimulatory molecules |
| 01/03/2002 | CA2411545A1 Tripeptide prodrug compounds |
| 01/03/2002 | CA2409408A1 Modulation of chromosome function by chromatin remodeling agents |
| 01/03/2002 | CA2408424A1 Use of urokinase inhibitors for the treatment and/or prevention of pulmonary hypertension and/or cardiac remodelling |
| 01/03/2002 | CA2381338A1 Human lyases |
| 01/03/2002 | CA2381241A1 Truncated egf receptor |
| 01/02/2002 | EP1167527A1 Processed human chemokines PHC-1 and PHC-2 |
| 01/02/2002 | EP1167526A1 IgE-dependent histamine-releasing factor(HRF)receptor, HRF-binding peptides and nucleic acids encoding the same, and uses thereof |
| 01/02/2002 | EP1167390A1 Crystals and structural coordinate of protein complex and utilisation of the structural coordinate |
| 01/02/2002 | EP1167388A1 Single-stranded fv inducing apoptosis |
| 01/02/2002 | EP1167385A2 Human follicle stimulating hormone receptor |
| 01/02/2002 | EP1167384A1 HVEGF Receptor as Vascular endothelial cell growth factor antagonists |
| 01/02/2002 | EP1167383A1 Novel conjugates of opioids and endogenous carriers |
| 01/02/2002 | EP1167382A1 Influenza virus hemagglutinin-binding peptides |
| 01/02/2002 | EP1166796A2 Agents for preventing and treating thrombocytopenia |
| 01/02/2002 | EP1166795A2 Skin cancer preventive agent containing sericin |
| 01/02/2002 | EP1166794A2 Method of treating retained pulmonary secretions |
| 01/02/2002 | EP1166793A1 Treatment of neuromuscular disorders and conditions with different botulinum serotype |
| 01/02/2002 | EP1166781A1 Proteasome inhibitors |
| 01/02/2002 | EP1166778A2 The use of growth hormone scretagogues to treat systemic lupus erythematosus and inflammatory bowel disease |
| 01/02/2002 | EP1166765A2 Process for protecting human skin |
| 01/02/2002 | EP1166123A2 Interactions of ku polypeptides |
| 01/02/2002 | EP1166102A1 Heart abnormalities in vascular endothelial growth factor b (vegf-b) deficient animals and methods relating to these heart abnormalities |
| 01/02/2002 | EP1165835A2 GENOMIC SEQUENCE OF THE $i(PURH) GENE AND $i(PURH)-RELATED BIALLELIC MARKERS |
| 01/02/2002 | EP1165828A1 50 human secreted proteins |
| 01/02/2002 | EP1165827A1 45 human secreted proteins |
| 01/02/2002 | EP1165818A2 Therapy of cancer by insect cells containing recombinant baculovirus encoding genes |
| 01/02/2002 | EP1165812A2 Protozoan expression system |
| 01/02/2002 | EP1165807A1 A protease, a gene therefor and the use thereof |
| 01/02/2002 | EP1165805A1 Dsp-2 dual-specificity map kinase phosphatase |
| 01/02/2002 | EP1165796A2 Recombinant clostridium toxin a protein carrier for polysaccharide conjugate vaccines |
| 01/02/2002 | EP1165795A2 Streptococcus pneumoniae antigens |
| 01/02/2002 | EP1165791A2 Human cytokine as ligand of the zalpha receptor and uses thereof |
| 01/02/2002 | EP1165789A2 Vesicle associated proteins |
| 01/02/2002 | EP1165788A2 Molecules of the immune system |
| 01/02/2002 | EP1165785A1 48 human secreted proteins |
| 01/02/2002 | EP1165784A2 Nucleic acids including open reading frames encoding polypeptides; "orfx" |
| 01/02/2002 | EP1165781A2 Protease resistant flint analogs |
| 01/02/2002 | EP1165780A2 Flint polypeptide analogs |
| 01/02/2002 | EP1165778A2 Casb618 polynucleotides and polypeptides and their use |
| 01/02/2002 | EP1165776A1 TYROSINE KINASE RECEPTOR EphA3 ANTIGENIC PEPTIDES |
| 01/02/2002 | EP1165774A2 Casb619 involved in colon cancers |
| 01/02/2002 | EP1165772A1 Protein-protein complexes from s. cerevisiae and methods of using same |
| 01/02/2002 | EP1165761A2 Methods for altering substrate specificity of phosphoinositide-dependent-protein kinase 1 (pdk1) |
| 01/02/2002 | EP1165758A2 Regulation of the expression of transcriptional repressor genes using nucleic acid molecules |
| 01/02/2002 | EP1165617A2 Anti-plasmodium compositions and methods of use |
| 01/02/2002 | EP1165616A1 Monoclonal antibodies, antigens and diagnosis and therapy of malignant diseases |
| 01/02/2002 | EP1165613A1 Melanocortin receptor ligands |
| 01/02/2002 | EP1165612A2 A method for purifying human growth hormone |